Ultralife Corporation (NASDAQ:ULBI - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.48 and traded as high as $9.11. Ultralife shares last traded at $8.68, with a volume of 87,966 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded shares of Ultralife from a "buy" rating to a "strong-buy" rating in a research report on Friday, June 6th.
Read Our Latest Stock Report on Ultralife
Ultralife Stock Down 3.1%
The company has a quick ratio of 1.70, a current ratio of 3.22 and a debt-to-equity ratio of 0.37. The firm has a market cap of $146.20 million, a P/E ratio of 27.47 and a beta of 1.00. The stock's 50-day simple moving average is $6.78 and its 200 day simple moving average is $6.49.
Ultralife (NASDAQ:ULBI - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The technology company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.02). The firm had revenue of $50.75 million for the quarter, compared to the consensus estimate of $54.50 million. Ultralife had a net margin of 3.05% and a return on equity of 4.61%. During the same period last year, the company posted $0.21 EPS.
Insider Transactions at Ultralife
In other Ultralife news, Director Bradford T. Whitmore bought 16,063 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were bought at an average price of $5.47 per share, for a total transaction of $87,864.61. Following the acquisition, the director directly owned 1,045,947 shares of the company's stock, valued at approximately $5,721,330.09. The trade was a 1.56% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas Louis Saeli bought 5,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was acquired at an average price of $5.44 per share, for a total transaction of $27,200.00. Following the acquisition, the director directly owned 85,000 shares in the company, valued at $462,400. The trade was a 6.25% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 47,140 shares of company stock worth $256,355 in the last three months. Insiders own 40.00% of the company's stock.
Institutional Investors Weigh In On Ultralife
A number of institutional investors and hedge funds have recently made changes to their positions in ULBI. Visionary Wealth Advisors increased its stake in Ultralife by 17.1% in the 4th quarter. Visionary Wealth Advisors now owns 1,292,836 shares of the technology company's stock valued at $9,632,000 after buying an additional 188,384 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Ultralife by 0.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,053,613 shares of the technology company's stock valued at $7,849,000 after buying an additional 7,174 shares during the last quarter. Renaissance Technologies LLC increased its stake in Ultralife by 11.6% in the 4th quarter. Renaissance Technologies LLC now owns 256,090 shares of the technology company's stock valued at $1,908,000 after buying an additional 26,700 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Ultralife by 13.2% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 178,170 shares of the technology company's stock valued at $1,327,000 after buying an additional 20,840 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Ultralife by 8.0% in the 4th quarter. Northern Trust Corp now owns 87,633 shares of the technology company's stock valued at $653,000 after buying an additional 6,484 shares during the last quarter. Institutional investors and hedge funds own 30.68% of the company's stock.
Ultralife Company Profile
(
Get Free Report)
Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.
Recommended Stories
Before you consider Ultralife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.
While Ultralife currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.